AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03217292
Drug: IV patient-controlled analgesia (PCA) tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02572453
Drug: Onalespib
RxNorm normalized name: Onalespib
DrugBank: Onalespib (DB06306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02906683
Drug: TAS-303
RxNorm normalized name: TAS-303
DrugBank: TAS-303 (DB18808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for 8 weeks, once daily.
Trial: NCT04339218
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
Trial: NCT04339218
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
Trial: NCT04339218
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be prescribed and administered at the dose recommended by market authorization.
Trial: NCT02965924
Drug: Phenylephrine 2.5%
RxNorm normalized name: PHENYLEPHRINE 2.5%/TROPICAMIDE 1% SOLN,OPH
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Instilling phenylephrine 2.5% eye drop
Trial: NCT04212169
Drug: MEDI3506
RxNorm normalized name: MEDI3506
DrugBank: MEDI3506 (DB16473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses
Trial: NCT00511472
Drug: LANTUS insulin
RxNorm normalized name: insulin glargine Injectable Solution [Lantus]
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
Trial: NCT05545462
Drug: Doxycyclin
RxNorm normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
Trial: NCT02146456
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02778711
Drug: secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: anti-IL-17
Trial: NCT04552197
Drug: JNJ-64251330
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64251330 tablet will be administered orally.
Trial: NCT04552197
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib tablets will be administered orally.
Trial: NCT02151721
Drug: Vorinostat, gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
Trial: NCT00572390
Drug: oestrogen
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclic oestrogen substitution therapy
Trial: NCT03618654
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00290043
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00003686
Drug: pilocarpine hydrochloride
RxNorm normalized name: Pilocarpine Hydrochloride
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine 5 mg po qid x 4 weeks
Trial: NCT00243243
Drug: Recombinant Factor VIIa
RxNorm normalized name: Human recombinant factor VIIa variant (P10Q, K32E, T106N, V253N), desialylated
DrugBank: CT-001 (DB18284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of Factor VIIa
Trial: NCT01556217
Drug: JNJ-39393406
RxNorm normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
Trial: NCT00454298
Drug: AGG-523 (Aggrecanase Inhibitor)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: AGG-523 (DB15460)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00562406
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
Trial: NCT03272126
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin D given as bolus versus daily dosing
Trial: NCT00565539
Drug: PEGylated recombinant interleukin 29 (PEG-rIL-29)
RxNorm normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous administration either weekly or every other week
Trial: NCT00000575
Drug: Nedocromil
RxNorm normalized name: NEDOCROMIL
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four 2 mg puffs bid + two 90 Og puffs albuterol prn
Trial: NCT00000575
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
Trial: NCT05198141
Drug: Letrozole tablets
RxNorm normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
Trial: NCT00282217
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01932385
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02215382
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sugammadex 2 mg/kg
Trial: NCT01426815
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
Trial: NCT02990728
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
Trial: NCT02215382
Drug: neostigmine+atropine
RxNorm normalized name: atropine / neostigmine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
Trial: NCT03876925
Drug: CT053PTSA
RxNorm normalized name: Ct053ptsa free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
Trial: NCT00889018
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
Trial: NCT00889018
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
Trial: NCT00942136
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
Trial: NCT01658826
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg oral administration
Trial: NCT01584713
Drug: Adipose-derived stem cells without expanded
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Trial: NCT03372486
Drug: Bupivacaine plus naloxone
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
Trial: NCT02739373
Drug: BMS-986189
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04290169
Drug: IncobotulinumtoxinA
RxNorm normalized name: incobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
Trial: NCT02881957
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00265746
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00169299
Drug: Black cohosh
RxNorm normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00169299
Drug: Multibotanical preparation
RxNorm normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00169299
Drug: Conjugated equine estrogen +/- medroxyprogesterone acetate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03372486
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
Trial: NCT05742022
Drug: Phospholipovit
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg orally 2 times a day, for 12 weeks
Trial: NCT04970940
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days
Trial: NCT02736604
Drug: nitrous oxide anesthesia
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
Trial: NCT02736604
Drug: air anesthesia
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
Trial: NCT02736604
Drug: sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01315496
Drug: Immunoglobulin G
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin 1.5-2g/Kg/3days
Trial: NCT01377051
Drug: Indacaterol maleate
RxNorm normalized name: Indacaterol Maleate
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dry powered, 300 mcg, only one inhalation with 24 hours duration
Trial: NCT02218463
Drug: Cetaphil
RxNorm normalized name: CETAPHIL
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Trial: NCT04025567
Drug: vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,500 mg total daily dose, on days 1-21 of every 28 days cycle.
Trial: NCT01413854
Drug: sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet two times daily during four weeks
Trial: NCT00658684
Drug: fesoterodine fumarate
RxNorm normalized name: Fesoterodine Fumarate
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
Trial: NCT00879112
Drug: MB07811
RxNorm normalized name: MB07811
DrugBank: MB07811 (DB05192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03944473
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent
Trial: NCT03944473
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
Trial: NCT04443192
Drug: ZF874
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.
Trial: NCT02958761
Drug: hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
Trial: NCT00322205
Drug: zyban
RxNorm normalized name: Zyban
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02912195
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
Trial: NCT02912195
Drug: Intravenous morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emergency department provider chooses appropriate dose of intravenous morphine
Trial: NCT01084122
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
Trial: NCT00972712
Drug: Bortezomib and Tipifarnib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)
Trial: NCT01260662
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
Trial: NCT01260662
Drug: 1:1 Propofol/Ketamine
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
Trial: NCT01260662
Drug: 4:1 Propofol/Ketamine
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
Trial: NCT01075776
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% intra-arterially 0.5ml/min
Trial: NCT02366871
Drug: Oral apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
Trial: NCT02366871
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
Trial: NCT00325637
Drug: cilnidipine
RxNorm normalized name: Cilnidipine
DrugBank: Cilnidipine (DB09232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine 10\~20mg, qd, po for 4 weeks.
Trial: NCT02980679
Drug: CTC
RxNorm normalized name: DMCTC
DrugBank: Demeclocycline (DB00618)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After injection of CTC, a whole body and thyroid scan will be performed.
Trial: NCT02980679
Drug: G-PERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After injection of G-PERT, a whole body and thyroid scan will be performed.
Trial: NCT03261635
Drug: Ranibizumab Injection
RxNorm normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
Trial: NCT01275053
Drug: leptin
RxNorm normalized name: Leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01mg/kg
Trial: NCT00336921
Drug: Alfuzosin
RxNorm normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT06204185
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Locally delivered Metformin gel in the treatment of periodontitis patients
Trial: NCT01427907
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
Trial: NCT03925896
Drug: LMP2 Antigen-specific TCR T cells
RxNorm normalized name: Neoantigen specific TCR-T cell therapy
DrugBank: Neoantigen specific TCR-T cell therapy (DB17458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
Trial: NCT00062894
Drug: Iodine I 131 Tositumomab
RxNorm normalized name: iodine I 131 tositumomab
DrugBank: Tositumomab I-131 (DB17991)
FDA approved: no
EMA approved: no
PMDA approved: no